San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

Analysis from the MONALEESA and RIBANNA trials in patients with HR-positive/HER2-negative advanced breast cancer finds differences in PFS among patients treated with ribociclib in combination with endocrine therapy among MONALEESA-like subgroups. Read More ›

Results from the MONALEESA trials show that PFS benefit with ribociclib in combination with endocrine therapy found to be consistent regardless of expression levels of most cell cycle genes. Read More ›

Comprehensive analysis of acquired resistance mutations in patients with HR-positive/HER2-negative advanced breast cancer post-CDK4/6 inhibitor and endocrine therapy is the largest to date. Read More ›


Interim analysis of the RIBANNA trial demonstrates that ribociclib provides a meaningful PFS benefit and maintains QOL in patients with HR-positive/HER2-negative advanced breast cancer. Read More ›

Several novel breast cancer therapies have come onto the market in recent years, significantly changing the breast cancer landscape, specifically in the metastatic setting. The Pathways Heart Study has looked at cardiovascular outcomes and risk variables from breast cancer treatments. A number of breast cancer risk factors as well as the benefits of physical exercise and aspirin use among breast cancer survivors are discussed in this review. Read More ›

Tucatinib added to trastuzumab and capecitabine resulted in a substantial and permanent improvement of progression-free survival and overall survival for all patients with HER2-positive metastatic breast cancer with brain metastases, as confirmed by results from the HER2CLIMB study. Read More ›

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, shares topics presented at the 2021 San Antonio Breast Cancer Symposium to help empower patients with breast cancer. Read More ›

Tucatinib-containing therapy resulted in a tumor volume reduction of >80%. Tucatinib was found to be highly effective when combined with paclitaxel plus trastuzumab plus pertuzumab. Read More ›

Tyrosine kinase inhibitor (TKI) treatments show equal overall survival and progression-free survival (PFS) benefits in patients with HER2-positive breast cancer with and without brain metastases. Read More ›

Page 5 of 12

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications